---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003052"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T23:05:17.150665+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q1 ORLADEYO rev $148.3M (+11% YoY); non-GAAP op profit $54.2M; licenses EU navenibart rights for $70M upfront

## Summary
- ORLADEYO net revenue $148.3M, +11% reported, +21% ex-Europe; GAAP operating loss $701.6M includes $697.8M non-cash IPR&D charge from Astria acquisition.
- Non-GAAP operating profit of $54.2M; guidance reaffirmed: FY2026 ORLADEYO rev $625-645M, total rev $635-660M, op ex $450-470M.
- Licensed European navenibart rights to Neopharmed Gentili for $70M upfront, up to $275M milestones, plus 18-30% royalties.
- Navenibart pivotal study ALPHA-ORBIT enrollment on track to complete by June 2026; US regulatory filing targeted by end 2027.
- Appointed Sandeep Menon as Chief R&D Officer in April; ended avoralstat DME program to focus on rare diseases.

## SEC filing metadata
- accession: 0001171843-26-003052
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/0001171843-26-003052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/f8k_050626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003052
- JSON: https://secwatch.observer/filing/0001171843-26-003052.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003052.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC updated its the quarter ended March 31, 2026 guidance (reaffirmed).
  - Period: the quarter ended March 31, 2026
  - Guidance: reaffirmed
  - Result: reported results
  source text: BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/0001171843-26-003052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.